Adalimumab, Risankizumab — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-09 (month) in 2mo
ESTIMATED |
READOUT
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug M
Phase 3 · Juvenile Psoriatic Arthritis |
ABBV AbbVie Inc. | Adalimumab, Risankizumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|